A broad spectrum of autoimmunity is now well described in patients with primary immunodeficiencies (PIDs). Management of autoimmune disease in the background of PID is particularly challenging given the seemingly discordant goals of immune support and immune suppression. Our growing ability to define the molecular underpinnings of immune dysregulation has facilitated novel targeted therapeutics. This review focuses on mechanism-based treatment strategies for the most common autoimmune and inflammatory complications of PID including autoimmune cytopenias, rheumatologic disease, and gastrointestinal disease. We aim to provide guidance regarding the rational use of these agents in the complex PID patient population.
|Number of pages||12|
|Journal||Journal of Allergy and Clinical Immunology: In Practice|
|State||Published - Nov 1 2016|
- Autoimmune enteropathy (AIE)
- Inflammatory bowel disease (IBD)
- Primary immunodeficiencies (PIDs)